Cohort1: Fovista_bevacizumab
|
Administration route |
intravitreal injection |
Dosage |
1.5 mg |
Pts |
21 |
Age |
Adult, Older_Adult |
Adverse reactions |
3/21(Infections and infestations) |
|
Cohort2: Fovista_ranibizumab
|
Administration route |
intravitreal injection |
Dosage |
1.5 mg |
Pts |
21 |
Age |
Adult, Older_Adult |
Adverse reactions |
3/21(Eye disorders; Injury, poisoning and procedural complications; Respiratory, thoracic and mediastinal disorders) |
|
Cohort3: Fovista_aflibercept
|
Administration route |
intravitreal injection |
Dosage |
1.5 mg |
Pts |
21 |
Age |
Adult, Older_Adult |
Adverse reactions |
5/21(Cardiac disorders; General disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified, incl cysts and polyps; Renal and urinary disorders) |
|